Jay Duffner
Associate Director - Discovery Biology Frontier Medicines
Seminars
Discussion Points Include:
- Explore strategies for prioritizing which biophysical assays to deploy first across diverse target classes
- Discuss how to balance high-throughput screens with deeper mechanistic assays to build confidence in early hits
- Examine how to define “confidence” in binding and progression decisions for challenging modalities, including fragments, PROTACs, intrinsically disordered proteins, and RNA-binding targets
- Share insights into managing conflicting or ambiguous data and deciding which hits to advance
This interactive, session explore the key lessons, tools, and strategies shared across the summit, and invites participants to reflect on what they will take back to their organizations. This session brings together experimentalists, computational biophysicists, and AI specialists to explore the bigger picture providing you the opportunity to have honest conversations with your industry colleagues about the biggest opportunities for biophysics to evolve across discovery, screening, and analytical development.
Key Discussion Themes:
- What did you learn that will meaningfully change your approach to biophysics, in screening, characterization, or developability?
- Which techniques, workflows, or decision-making frameworks will you apply immediately in your own programs?
- Where are the biggest gaps in current biophysical capabilities and what innovations do we want to see from vendors, academia, and internal R&D in the next 3–5 years?
- How can discovery and analytical groups collaborate more effectively to reduce friction, avoid rework, and increase translational success?
- Which complex targets or modalities remain ‘unsolved,’ and what new tools or cross-functional integrations are needed to unlock them?
Blue Sky Thinking & Audience Feedback: What does the ideal future-state biophysical toolbox look like? High-throughput? Label-free? More physiologically relevant? AI-integrated?
